Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Towa Pharmaceutical Co ( (JP:4553) ) just unveiled an update.
Towa Pharmaceutical Co., Ltd. reported a strong financial performance for the year ended March 31, 2025, with net sales increasing by 13.9% to ¥259,594 million and operating profit rising by 31.7% to ¥23,242 million. The company also announced an increase in dividends, reflecting its robust financial health and commitment to returning value to shareholders. The positive results indicate a solid market position and potential for future growth, benefiting stakeholders and reinforcing its competitive stance in the pharmaceutical industry.
The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3000.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
More about Towa Pharmaceutical Co
Towa Pharmaceutical Co., Ltd. is a company listed on the Tokyo Stock Exchange, primarily operating in the pharmaceutical industry. It focuses on the production and distribution of generic drugs, serving a significant role in providing cost-effective medication solutions.
Average Trading Volume: 121,118
Technical Sentiment Signal: Hold
Current Market Cap: Yen130.6B
Learn more about 4553 stock on TipRanks’ Stock Analysis page.